Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Business & Finance
Pharma company receives royalty payment from Solae LLC
February 17th, 2005
Pharmaceutical company Novogen Limited (NASDAQ:NVGN) received its latest milestone royalty payment of $863,000 under a license agreement with Solae LLC (a joint venture between DuPont's Protein Technologies International and Bunge Limited). The companies entered the license agreement in November 1997, and the relevant patent applications are now at various stages of issue around the world. Solae has the worldwide rights (other than for Australia and New Zealand) to certain Novogen soy isoflavone technology. Novogen has retained all rights to its own red clover-based isoflavone technologies. The Solae license relates specifically to Novogen patents or...
Source: Women's Health Weekly (2005-02-17)
|
